Trial Profile
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Adverse reactions
- Sponsors Kyowa Kirin Pharmaceutical Development
- 21 Nov 2023 Planned End Date changed from 1 Apr 2024 to 1 Mar 2024.
- 09 Feb 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 25 Jan 2023 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.